Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial. [electronic resource]
Producer: 20201026Description: 7370-7380 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor -- blood
- Drug Resistance, Neoplasm
- Female
- GTP Phosphohydrolases -- genetics
- Humans
- Male
- Membrane Proteins -- genetics
- Middle Aged
- Mutation
- Neoplasm Grading
- Progression-Free Survival
- Protein Kinase Inhibitors -- therapeutic use
- Proto-Oncogene Proteins B-raf -- genetics
- Retrospective Studies
- Sorafenib -- therapeutic use
- Thyroglobulin -- blood
- Thyroid Neoplasms -- blood
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- blood
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.